3D QSAR of aminophenyl benzamide derivatives as histone deacetylase inhibitors

Medicinal Chemistry

Volumn 6, Issue 5, 2010, Pages 277-285

  Mahipal, ^a   Tanwar, Om Prakash ^a   Karthikeyan, C ^a   Moorthy, N S Hari Narayana ^a,b   Trivedi, Piyush ^a  

^a UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Aminophenyl benzamide; Histone deacetylases inhibitors; Pharmacophore; PHASE; QSAR; Schrodinger

Indexed keywords

AMINOPHENYL BENZAMIDE DERIVATIVE; AROMATIC COMPOUND; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ATOM; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; ELECTRON TRANSPORT; GEOMETRY; HYDROGEN BOND; HYDROPHOBICITY; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BENZAMIDES; DRUG DESIGN; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HYDROGEN BONDING; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650194240     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340610793358846     Document Type: Article

References (23)

1. Wolffe, A.P.; Matzke, M.A. Epigenetics: Regulation through repression. Science, 1999, 286, 481-486.
2. Marks, P.A.; Rifkind, R.A.; Richon, V.M.; Breslow, R.; Miller, T.; Kelly, W.K. Histone deacetylases and cancer: Causes and therapies. Nat. Rev. Cancer, 2001, 1, 194-202. (Pubitemid 33741894)
3. Oki, Y.; Issa, J.P. Review: Recent clinical trials in epigenetic therapy. Rev. Recent Clin. Trials, 2006, 1, 169-182.
4. Batty, N.; Malouf, G.G.; Issa J.P. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett., 2009, 280, 192-200.
5. Cesare, G.; Antonio, R.; Paolo, M. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Critical Rev. Oncol./Hematol., 2008, 68, 29-36.
6. Kim, Y.B.; Lee, K.H.; Sugita, K.; Yoshida, M.; Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene, 1999, 18, 2461-2470. (Pubitemid 29206159)
7. Meinke, P.T.; Liberator, P. Histone deacetylase: A target for antiproliferative and antiprotozoal agents. Curr. Med. Chem., 2001, 8, 211-235. (Pubitemid 32416448)
8. Breslow, R.; Belvedere, S.; Gershell, L.; Miller, T.A.; Marks, P.A.; Richon, V.M.; Rifkind, R. Class of cytodifferentiating agents and histone deacetylase inhibitors, and method of use thereof. Patent Application US, 6511990-B1, 2003.
9. Kelly, W.K.; Richon V.M.; O'Connor, O.; Curley, T.; MacGregor, C.B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon, C.C.; Chiao, J.H.; Rifkind, R.; Marks, P.A.; Scher, H. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol., 2005, 23, 3923-3931. (Pubitemid 46218695)
10. Duvic, M.; Vu, J. Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Invest. Drugs, 2007, 16, 1111-1120. (Pubitemid 47074165)
11. Sampath, K.A.; John, S.; Ward, R.D.; Brokx; Trisha, D.; Mark, R.B.; Dinesh, V.P.; Xiao, Y.X. Design and synthesis of thiazole-5- hydroxamic acids as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 5995-5999.
12. Paquin,I.; Raeppel, S.; Leit, S.; Gaudette, F.; Zhou, N.; Moradei, O.; Saavedra, O.; Bernstein, N.; Raeppel, F.; Bouchain, G.; Frechette, S.; Woo, S.H.; Vaisburg, A.; Fournel, M.; Kalita, A.; Robert, M-F.; Lu, A.; Trachy-Bourget, M-C.; Yan, P.T.; Liu, J.; Rahil, J.; MacLeod, A.R.; Besterman, J.M.; Li, Z.; Delorme, D. Design and synthesis of 4-[(s-triazin-2-ylamino) methyl]-N-(2-aminophenyl)- benzamides and their analogues as a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 1067-1071. (Pubitemid 351179338)
13. Ester, M.; Sergio, A.; Danila, B.; Ottavia, C.; Federica, F.; Maria, V.O.; Maria, C.P.; Michael, R.; Rita, S.; Christian, S.; Philip, J. 2- Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 6083-6087.
14. Shoukou, L.; Chihiro, S.; Kiyoshi, O.; Motomu, S.; Satoko, M.; Mayumi, S.; Minoru, Y.; Yuichi, H.; Hiroyuki, M. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 4895-4900.
15. Suzuki, T.; Miyata, N. Non-hydroxamate histone deacetylase inhibitors. Curr. Med. Chem., 2005, 12(24), 2867-2880. (Pubitemid 41601562)
16. Moradei, O.; Leit, S.; Zhou, N.; Frechette, S.; Paquin, I.; Raeppel, S.; Gaudette, F.; Bouchain, G.; Woo, S.H.; Vaisburg, A.; Fournel, M.; Kalita, A.; Lu, A.; Trachy- Bourget, M.-C.; Yan, P.T.; Liu, J.; Li, Z.; Rahil, J.; MacLeod, A.R.; Besterman, J.M.; Delorme, D. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)- acrylamides and their analogues: Novel classes of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 4048-4052. (Pubitemid 43903209)
17. Frechette, S.; Leit, S.; Hyung, S.; Lapointe, G.; Jeannotte, G.; Moradei, O.; Paquin, I.; Raeppel, S.; Leit, S.; Gaudette, F.; Zhou, N.; Moradei, O.; Saavedra, O.; Bernstein, N.; Raeppel, F.; Bouchain, G.; Frechette, S.; Woo, S.; Vaisburg, A.; Fournel, M.; Kalita, A.; Robert, M.; Lu, A.; Claude, M.; Bourget, T.; Yan, T.; Liu, J.; Rahil, A.; MacLeod, R.; Besterman, J.L.; Delorme, Z. 4- (Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 1502-1506. (Pubitemid 351226519)
18. Jaiswal, D.; Karthikeyan, C.; Trivedi, P. Rationalization of physicochemical properties of alkanoic acid derivatives towards histone deacetylase inhibition. Internet Electron. J. Mol. Des., 2006, 5, 13-26.
19. Jaiswal, D.; Karthikeyan, C.; Shrivastava, S.K.; Trivedi, P. QSAR modeling of sulfonamide inhibitors of histone deacetylase. Internet Electron. J. Mol. Des., 2006, 5, 345-54.
20. Samantha, L.; Cesare, M.; Aleksey, K.; Mattia, S.; Stefano, M.; Elena, C.; Dorotea, R.; Alessandro, C. SAR and QSAR study on 2- aminothiazole derivatives, modulators of transcriptional repression in Huntington's disease. Bioorg. Med. Chem. Lett. 2008, 16, 5695-5703.
21. User manual Phase, version 3.0, Schrödinger, LLC, New York, NY, 2008.
22. Dixon, S.L.; Smondyrev, A.M.; Knoll, E.H.; Rao, S.N.; Shaw, D.E.; Friesner, R.A. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des., 2006, 20, 647-671. (Pubitemid 46023928)
23. Shah, U.A.; Deokar, H.S.; Kadam, S.S.; Kulkarni, V.M. Pharmacophore generation and atom-based 3D-QSAR of novel 2-(4- methylsulfonylphenyl) pyrimidines as COX-2 inhibitors. Mol. Divers., 2010. DOI 10.1007/s11030-009- 9183-3.